cas 196929-78-9|| where to buy (R)-2-methylpropane-2-sulfinamide

Produktname:(R)-2-methylpropane-2-sulfinamide

IUPAC Name:(R)-2-methylpropane-2-sulfinamide

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM112195-200g	in stock	ȷƋ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 196929-78-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:196929-78-9; Molekulare Formel:C4H11NOS; Schmelzpunkt:-; SMILES-Code:CC([S@](N)=O)(C)C; Dichte:

: Katalognummer:CM112195; Molekulargewicht:121.2; Siedepunkt:; Mdl-Nr.:MFCD05861479; Lagerung:Keep in a tight container and store at 2°C~8°C

: Nitrogen Compounds; Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.

: Repotrectinib; Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.

: Olutasidenib; Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.